These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 16538227)

  • 1. Huntington's disease: A transcriptional report card from the peripheral blood: can it measure disease progression in Huntington's disease?
    Tabchy A; Housman D
    Eur J Hum Genet; 2006 Jun; 14(6):649-50. PubMed ID: 16538227
    [No Abstract]   [Full Text] [Related]  

  • 2. Gene expression changes in blood as a putative biomarker for Huntington's disease.
    Lovrecic L; Kastrin A; Kobal J; Pirtosek Z; Krainc D; Peterlin B
    Mov Disord; 2009 Nov; 24(15):2277-81. PubMed ID: 19844910
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blood level of brain-derived neurotrophic factor mRNA is progressively reduced in rodent models of Huntington's disease: restoration by the neuroprotective compound CEP-1347.
    Conforti P; Ramos C; Apostol BL; Simmons DA; Nguyen HP; Riess O; Thompson LM; Zuccato C; Cattaneo E
    Mol Cell Neurosci; 2008 Sep; 39(1):1-7. PubMed ID: 18571429
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DNA microarray analysis of striatal gene expression in symptomatic transgenic Huntington's mice (R6/2) reveals neuroinflammation and insulin associations.
    Crocker SF; Costain WJ; Robertson HA
    Brain Res; 2006 May; 1088(1):176-86. PubMed ID: 16626669
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The relationship between CAG repeat length and clinical progression in Huntington's disease.
    Ravina B; Romer M; Constantinescu R; Biglan K; Brocht A; Kieburtz K; Shoulson I; McDermott MP
    Mov Disord; 2008 Jul; 23(9):1223-7. PubMed ID: 18512767
    [TBL] [Abstract][Full Text] [Related]  

  • 6. On the pathological progression of Huntington's disease.
    Sieradzan KA; Mann DM
    Ann Neurol; 1998 Jul; 44(1):148-9. PubMed ID: 9667607
    [No Abstract]   [Full Text] [Related]  

  • 7. Striatal specificity of gene expression dysregulation in Huntington's disease.
    Thomas EA
    J Neurosci Res; 2006 Nov; 84(6):1151-64. PubMed ID: 16983659
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of potential transcriptomic biomarkers for Huntington's disease in peripheral blood.
    Runne H; Kuhn A; Wild EJ; Pratyaksha W; Kristiansen M; Isaacs JD; Régulier E; Delorenzi M; Tabrizi SJ; Luthi-Carter R
    Proc Natl Acad Sci U S A; 2007 Sep; 104(36):14424-9. PubMed ID: 17724341
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Distinct neuroinflammatory profile in post-mortem human Huntington's disease.
    Silvestroni A; Faull RL; Strand AD; Möller T
    Neuroreport; 2009 Aug; 20(12):1098-103. PubMed ID: 19590393
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic markers of Huntington's disease discovered.
    Bartlett S
    Lancet Neurol; 2005 Oct; 4(10):602. PubMed ID: 16208874
    [No Abstract]   [Full Text] [Related]  

  • 11. ADP-ribosylation factor guanine nucleotide-exchange factor 2 (ARFGEF2): a new potential biomarker in Huntington's disease.
    Lovrecic L; Slavkov I; Dzeroski S; Peterlin B
    J Int Med Res; 2010; 38(5):1653-62. PubMed ID: 21309479
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Huntington's disease biomarker progression profile identified by transcriptome sequencing in peripheral blood.
    Mastrokolias A; Ariyurek Y; Goeman JJ; van Duijn E; Roos RA; van der Mast RC; van Ommen GB; den Dunnen JT; 't Hoen PA; van Roon-Mom WM
    Eur J Hum Genet; 2015 Oct; 23(10):1349-56. PubMed ID: 25626709
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RNA stabilization of peripheral blood and profiling by bead chip analysis.
    Debey-Pascher S; Eggle D; Schultze JL
    Methods Mol Biol; 2009; 496():175-210. PubMed ID: 18839112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increase in bax expression and apoptosis are associated in Huntington's disease progression.
    Teles AV; Rosenstock TR; Okuno CS; Lopes GS; Bertoncini CR; Smaili SS
    Neurosci Lett; 2008 Jun; 438(1):59-63. PubMed ID: 18468793
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chromatin dysfunction in Huntington's disease.
    Cattaneo E
    Prog Neurobiol; 2007 Nov; 83(4):193-4. PubMed ID: 17706859
    [No Abstract]   [Full Text] [Related]  

  • 16. Phosphorus-31 magnetic resonance studies on blood in Huntington's disease.
    Pettegrew JW; Glonek T; Stewart RM
    Trans Am Neurol Assoc; 1979; 104():233-5. PubMed ID: 162254
    [No Abstract]   [Full Text] [Related]  

  • 17. [Mechanisms of neuronal death in Huntington's disease. Second part: therapeutic challenges].
    Bantubungi K; Blum D
    Rev Med Brux; 2007; 28(6):487-94. PubMed ID: 18265808
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Gene analysis of Huntington's disease].
    Kanazawa I
    Nihon Shinkei Seishin Yakurigaku Zasshi; 1995 Oct; 15(5):419-24. PubMed ID: 8564735
    [No Abstract]   [Full Text] [Related]  

  • 19. Animal models of Huntington's disease.
    Gárdián G
    Ideggyogy Sz; 2006 Nov; 59(11-12):396-9. PubMed ID: 17203874
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blood 5-hydroxytryptamine, 5-hydroxyindoleacetic acid and melatonin levels in patients with either Huntington's disease or chronic brain injury.
    Christofides J; Bridel M; Egerton M; Mackay GM; Forrest CM; Stoy N; Darlington LG; Stone TW
    J Neurochem; 2006 May; 97(4):1078-88. PubMed ID: 16573644
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.